A Fléchon, D Pouessel, C Ferlay, D Perol, P Beuzeboc, G Gravis, F Joly, S Oudard, G Deplanque, S Zanetta, P Fargeot, F Priou, J P Droz, S Culine
BACKGROUND: In the evolution of metastatic castration-resistant prostate cancer (mCRPC), patients present visceral metastases with or without neuroendocrine differentiation in 20% of cases. PATIENTS AND METHODS: We assessed the efficacy and toxicity of a platinum-based chemotherapy regimen in mCRPC patients with either neuroendocrine differentiation defined by high serum levels of chromogranin A (CgA) and neuron-specific enolase (NSE) or visceral metastases. Patients received the combination of carboplatin and etoposide every 3 weeks...
November 2011: Annals of Oncology: Official Journal of the European Society for Medical Oncology